Prothena (GB:0Y3M)
UK Market

Prothena Stock Analysis & Ratings

GB:0Y3M Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$35.8
Average Volume (3M)8.00
Market Cap$1.68B
P/E Ratio23.4
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score8
EPS (TTM)1.53



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Prothena’s market cap?
    Prothena’s market cap is $1.68B.
      What is Prothena’s price target?
      The average price target for Prothena is $65.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $75.00 ,the lowest forecast is $45.00. The average price target represents 81.56% Increase from the current price of $35.8.
        What do analysts say about Prothena?
        Prothena’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Prothena’s upcoming earnings report date?
          Prothena’s upcoming earnings report date is Aug 09, 2022 which is in 80 days.
            How were Prothena’s earnings last quarter?
            Prothena released its earnings results on May 05, 2022. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.691 by -$0.089.
              Is Prothena overvalued?
              According to Wall Street analysts Prothena’s price is currently Undervalued.
                Does Prothena pay dividends?
                Prothena does not currently pay dividends.
                What is Prothena’s EPS estimate?
                Prothena’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Prothena have?
                Prothena has 46,810,000 shares outstanding.
                  What happened to Prothena’s price movement after its last earnings report?
                  Prothena reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.691. Following the earnings report the stock price went same 0%.
                    Which hedge fund is a major shareholder of Prothena?
                    Among the largest hedge funds holding Prothena’s share is Maple Rock Capital Partners Inc.. It holds Prothena’s shares valued at 12M.


                      Prothena Stock Analysis

                      Smart Score
                      Price Target
                      ▲(81.56% Upside)
                      Strong Buy
                      The Prothena stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description


                      Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

                      Similar Stocks
                      Price & Change
                      Roche Holding
                      Horizon Therapeutics
                      ACADIA Pharmaceuticals
                      Voyager Therapeutics

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis